Round Table discussion - Role of Risk Stratification for Cardio Vascular Disease in the COVID-19 era and its economic benefits

Cardiovascular diseases (CVD) are considered a major global health problem. CVD is the leading cause of premature death worldwide, and it imposes a high burden on individuals, households, health systems, and societies. Because modifiable and preventable risk factors have a crucial influence on CVD morbidity and mortality, primary prevention is key to successfully reducing the burden of the disease.

Join this session to learn from a panel of experts in CVD prevention about 1) the recent evidence for using High Sensitive Troponin I (hsTnI) as a novel biomarker of CVD risk in asymptomatic populations; 2) an algorithm to incorporate hsTnI into risk prediction and clinical management as well as an example of the adoption of hsTnI in risk stratification; 3) the health economic implications of screening and risk assessment strategies in general and the current health economic evidence of using hsTnI for cardiovascular risk assessment and; 4) the implementation learnings and best practices shared by Medcan Clinic.

 

Learning Objectives

 

This webinar will be moderated by Dr. Christos Varounis, MD, MSc, MBA - Cardiologist, Medical Director, Medical Affairs, Abbot Core Diagnostics.